News
CLRB
--
0.00%
--
Cellectar Bio Stock Drops After ASCO Presentation on White Blood Cell Cancer Therapy
Benzinga · 06/04 19:13
SENS, ADMP, LPTH and NGL among midday movers
Gainers: SemiLEDs (LEDS) +66%.Senseonics (SENS) +49%.Windtree Therapeutics (WINT) +38%.MoSys (MOSY) +34%.Ra Medical Systems (RMED) +29%.LightPath Technologies (LPTH) +27%.American Superconductor (AMSC) +26%.Smart Sand (SND) +25%.The9 (NCTY) +24%.Vinco Vent...
Seekingalpha · 06/04 16:37
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 06/04 16:31
Cellectar shares fall after mid-stage CLR 131 trial data fails to impress
Cellectar Biosciences shares slide ([[CLRB]] -13.2%) after posting data from its mid-stage study of CLR 131 in patients with Waldenstrom’s macroglobulinemia ((WM)), a rare and incurable disease, at the American Society of Clinical Oncology ((ASCO))
Seekingalpha · 06/04 15:10
Windtree Therapeutics, Senseonics leads healthcare gainers; Harpoon Therapeutics, Purple Biotech among major losers
Gainers: Windtree Therapeutics (WINT) +57%, Senseonics (SENS) +38%, Ra Medical Systems (RMED) +22%, Cullinan Oncology (CGEM) +20%, Progenity (PROG) +10%.Losers: Harpoon Therapeutics (HARP) -25%, Purple Biotech (PPBT) -19%, Adamis Pharmaceuticals (ADMP) -16...
Seekingalpha · 06/04 15:03
Cellectar Biosciences Says Data From Trial Show 16.7% Complete Response Rate in Rare Blood Cancer Patients; Shares Down
MT Newswires · 06/04 14:55
Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Mean treatment free remission 1.1 years and remains ongoing Progression free survival for MYD88 wild type and high-risk patients 18 months and ongoing FLORHAM PARK, N.J., June 04, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-...
GlobeNewswire · 06/04 13:00
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 06/01 20:32
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.
Benzinga · 05/31 15:06
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 05/27 20:31
Cellectar Announces Poster Presentation Of CLR 131 Data In Waldenstrom's Macroglobulinemia At 2021 American Society of Clinical Oncology Annual Meeting
 Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a poster presentation
Benzinga · 05/20 12:35
Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021
FLORHAM PARK, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the company will...
GlobeNewswire · 05/14 13:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers
Benzinga · 05/12 20:34
10-Q: CELLECTAR BIOSCIENCES, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Overview We are a late-stage...
Edgar Online - (EDG = 10Q, 10K) · 05/10 12:51
Cellectar Biosciences EPS beats by $0.03
Cellectar Biosciences (CLRB): Q1 GAAP EPS of -$0.13 beats by $0.03.Cash and cash equivalents of $53.63M.Press Release
Seekingalpha · 05/10 12:44
BRIEF-Cellectar Biosciences Inc Posts Q1 Loss Per Share $0.13
reuters.com · 05/10 12:36
Cellectar Biosciences Q1 EPS $(0.13) Up From $(0.42) YoY
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.13) per share. This is a 69.05 percent increase over losses of $(0.42) per share from the same period last year.
Benzinga · 05/10 12:31
Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update
FLORHAM PARK, May 10, 2021 (GLOBE NEWSWIRE via COMTEX) -- Initiated pivotal study of CLR 131 in Waldenstrom's macroglobulinemia (WM)Received European Orphan...
GlobeNewswire · 05/10 12:30
8-K: Cellectar Biosciences, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 8-K ___________________ CURRENT REPORT (EDGAR Online via...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 05/04 04:37
Webull provides a variety of real-time CLRB stock news. You can receive the latest news about Cellectar through multiple platforms. This information may help you make smarter investment decisions.
About CLRB
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer-targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. Its PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The Company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900). The CLR 1900 Series is targeted for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers.